Oleoylethanolamide for Alcoholism

This trial explores whether a supplement called oleoylethanolamide (OEA) can assist young adults with alcohol use disorder (AUD) by influencing inflammation, the oral microbiome (the community of bacteria in the mouth), brain functions related to decision-making, and alcohol consumption habits. Participants will take either OEA or a placebo (a non-active substance) for six weeks. The study aims to determine if OEA can induce positive changes in the body and behavior for those struggling with AUD. Individuals aged 18 to 25 who regularly consume alcohol might be suitable candidates for this study. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant findings.

The trial information does not specify whether you need to stop taking your current medications. It's best to contact the study team for more details.

Research shows that oleoylethanolamide (OEA) is generally safe for people. Previous studies indicate that humans tolerate OEA well. This compound reduces inflammation and protects against damage in both the brain and body. A thorough safety review found that OEA manages inflammation and stress without causing major side effects.

Evidence from earlier research shows that OEA can reduce alcohol consumption in animal studies, suggesting its safety. Importantly, at least one human trial tested OEA in young adults with alcohol use disorder, and no major safety issues emerged.

Oleoylethanolamide (OEA) is unique because it targets the body's endocannabinoid system, which plays a role in regulating addiction and cravings. Unlike traditional treatments for alcoholism, such as disulfiram or naltrexone, which mainly focus on altering alcohol metabolism or blocking the pleasurable effects of alcohol, OEA is thought to help reduce the urge to drink by influencing appetite and reward pathways. Researchers are excited about OEA because it offers a potential new mechanism of action, possibly providing an alternative for individuals who do not respond well to existing therapies.

Research suggests that oleoylethanolamide (OEA), which participants in this trial may receive, might help reduce drinking and its harmful effects. Studies have shown that OEA acts as a strong anti-inflammatory, potentially protecting the brain from damage caused by heavy drinking. It may also help control the urge to drink by influencing how the brain processes rewards. In early tests, OEA lowered alcohol intake by altering how the body handles stress. Overall, initial findings indicate that OEA could be helpful in managing alcohol use disorder.¹²³⁴⁶